I am sure you have heard of the hubbub about price gouging for EpiPens ($100 to $600 in 10 years or so). A generic has just been qualified for an epipen equivalent:
However, FDA research indicates that one generic in the wild only means 20% discount on average (according to the FDA, price tumble only with several generics in the wild). It will be interesting to see what happens here. However, with the Mylan-owned generic at $300, I am not expecting anything lower than $250 at best, based on the Basaglar example.
I am coming to believe more and more that the only way to influence insulin prices is for the DOC to fund not-for-profit manufacturing of insulin that offers insulin for a reasonable profit margin but no more – and that would function as a price setter.
I find it really weird, btw, that average people are up in arms about an EpiPen that you may need once a year, but don’t seem to care about insulin prices that you need every month…